Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -23.15% is 29% above its 5-year average of -32.38%, near the high end of its 5-year range (-72.66%–-8.61%).
83.88% below its 12-month average of -12.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.23%.
RETURN ON ASSETS (ROA)
-23.15%
RETURN ON ASSETS (ROA) AVG TTM
-12.59%
RETURN ON ASSETS (ROA) AVG 3Y
-25.36%
RETURN ON ASSETS (ROA) AVG 5Y
-32.38%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-83.88%
CURRENT VS 3Y AVG
+8.71%
CURRENT VS 5Y AVG
+28.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
+26.20%
vs the sector median at left
Monte Rosa Therapeutics, Inc.
Market Cap
$841.42M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$840.18M
Return on Assets (ROA)
-23.03%
TTM Avg
-34.41%
3Y Avg
-34.41%
5Y Avg
-34.41%
Market Cap
$835.64M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
Market Cap
$833.62M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
Market Cap
$832.41M
Return on Assets (ROA)
-17.48%
TTM Avg
-47.13%
3Y Avg
-32.40%
5Y Avg
-21.92%
Market Cap
$858.87M
Return on Assets (ROA)
-18.34%
TTM Avg
-25.78%
3Y Avg
-11.37%
5Y Avg
4.46%
Market Cap
$861.70M
Return on Assets (ROA)
-5.88%
TTM Avg
-10.67%
3Y Avg
-19.76%
5Y Avg
-21.39%
Market Cap
$863.01M
Return on Assets (ROA)
-135.59%
TTM Avg
-77.84%
3Y Avg
-48.75%
5Y Avg
-48.75%
Market Cap
$865.07M
Return on Assets (ROA)
61.78%
TTM Avg
41.06%
3Y Avg
4.27%
5Y Avg
-3.43%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $841.42M | -23.15% | -12.59% | -25.36% | -32.38% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $840.18M | -23.03% | -34.41% | -34.41% | -34.41% |
| Alumis Inc. (ALMS)vs › | $835.64M | -78.30% | -72.68% | -105.45% | -105.45% |
| Beta Bionics, Inc. (BBNX)vs › | $833.62M | -24.96% | -29.43% | -70.30% | -70.30% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $832.41M | -17.48% | -47.13% | -32.40% | -21.92% |
| QuidelOrtho Corporation (QDEL)vs › | $858.87M | -18.34% | -25.78% | -11.37% | 4.46% |
| SI-BONE, Inc. (SIBN)vs › | $861.70M | -5.88% | -10.67% | -19.76% | -21.39% |
| SL Science Holding Ltd (SLBT)vs › | $863.01M | -135.59% | -77.84% | -48.75% | -48.75% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $865.07M | 61.78% | 41.06% | 4.27% | -3.43% |
| Jade Biosciences, Inc. (JBIO)vs › | $812.67M | -32.46% | -61.56% | -55.11% | -72.90% |
ROA
-23.1%
ROE
-33.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -8.61% |
| 2024-12-31 | -16.57% |
| 2023-12-31 | -44.56% |
| 2022-12-31 | -31.69% |
| 2021-12-31 | -20.19% |
| 2020-12-31 | -72.66% |
| 2019-12-31 | -72.26% |
